459 related articles for article (PubMed ID: 12454314)
1. Treatment for anthracycline-pretreated metastatic breast cancer.
O'Shaughnessy J; Twelves C; Aapro M
Oncologist; 2002; 7 Suppl 6():4-12. PubMed ID: 12454314
[TBL] [Abstract][Full Text] [Related]
2. Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline-pretreated metastatic breast cancer.
Verma S; Ilersich AL
Oncologist; 2003; 8(3):232-40. PubMed ID: 12773745
[TBL] [Abstract][Full Text] [Related]
3. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
O'Shaughnessy J; Miles D; Vukelja S; Moiseyenko V; Ayoub JP; Cervantes G; Fumoleau P; Jones S; Lui WY; Mauriac L; Twelves C; Van Hazel G; Verma S; Leonard R
J Clin Oncol; 2002 Jun; 20(12):2812-23. PubMed ID: 12065558
[TBL] [Abstract][Full Text] [Related]
4. Capecitabine: a review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer.
Wagstaff AJ; Ibbotson T; Goa KL
Drugs; 2003; 63(2):217-36. PubMed ID: 12515569
[TBL] [Abstract][Full Text] [Related]
5. Final results of a phase II clinical trial of weekly docetaxel in combination with capecitabine in anthracycline-pretreated metastatic breast cancer.
Mackey JR; Tonkin KS; Koski SL; Scarfe AG; Smylie MG; Joy AA; Au HJ; Bodnar DM; Soulieres D; Smith SW
Clin Breast Cancer; 2004 Oct; 5(4):287-92. PubMed ID: 15507175
[TBL] [Abstract][Full Text] [Related]
6. Capecitabine and docetaxel in advanced breast cancer: analyses of a phase III comparative trial.
O'Shaughnessy J
Oncology (Williston Park); 2002 Oct; 16(10 Suppl 12):17-22. PubMed ID: 12435175
[TBL] [Abstract][Full Text] [Related]
7. Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda) for locally advanced and/or metastatic breast cancer.
Jones L; Hawkins N; Westwood M; Wright K; Richardson G; Riemsma R
Health Technol Assess; 2004 Feb; 8(5):iii, xiii-xvi, 1-143. PubMed ID: 14960257
[TBL] [Abstract][Full Text] [Related]
8. [Docetaxel (Taxotere) in combination with anthracycline, capecitabin (Xeloda) and new drugs].
Galligioni E
Tumori; 2001; 87(1 Suppl 2):S1-9. PubMed ID: 11357871
[No Abstract] [Full Text] [Related]
9. Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trial.
Miles D; Vukelja S; Moiseyenko V; Cervantes G; Mauriac L; Van Hazel G; Liu WY; Ayoub JP; O'Shaughnessy JA
Clin Breast Cancer; 2004 Oct; 5(4):273-8. PubMed ID: 15507172
[TBL] [Abstract][Full Text] [Related]
10. Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results.
Michalaki V; Gennatas S; Gennatas K
Anticancer Drugs; 2009 Mar; 20(3):204-7. PubMed ID: 19174694
[TBL] [Abstract][Full Text] [Related]
11. Moving forward with capecitabine: a glimpse of the future.
Biganzoli L; Martin M; Twelves C
Oncologist; 2002; 7 Suppl 6():29-35. PubMed ID: 12454317
[TBL] [Abstract][Full Text] [Related]
12. Trastuzumab plus capecitabine and docetaxel as first-line therapy for HER2-positive metastatic breast cancer: phase II results.
Michalaki V; Fotiou S; Gennatas S; Gennatas C
Anticancer Res; 2010 Jul; 30(7):3051-4. PubMed ID: 20683054
[TBL] [Abstract][Full Text] [Related]
13. Docetaxel-anthracycline combinations in metastatic breast cancer.
Nabholtz JM
Breast Cancer Res Treat; 2003; 79 Suppl 1():S3-9. PubMed ID: 12868800
[TBL] [Abstract][Full Text] [Related]
14. A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer.
Karachaliou N; Ziras N; Syrigos K; Tryfonidis K; Papadimitraki E; Kontopodis E; Bozionelou V; Kalykaki A; Georgoulias V; Mavroudis D
Cancer Chemother Pharmacol; 2012 Jul; 70(1):169-76. PubMed ID: 22669571
[TBL] [Abstract][Full Text] [Related]
15. A multicentre phase II study to evaluate sequential docetaxel followed by capecitabine treatment in anthracycline-pretreated HER-2-negative patients with metastatic breast cancer.
Bayo J; Lomas M; Salvador J; Moreno A; Ruiz M; Rodríguez A; Fuentes J; Fernández-Freire A; Bernabé R; Fernández A
Clin Transl Oncol; 2008 Dec; 10(12):817-25. PubMed ID: 19068453
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine plus docetaxel: a new treatment option for anthracycline pretreated metastatic breast cancer patients?
Levy C; Fumoleau P
Cancer Treat Rev; 2005; 31 Suppl 4():S17-22. PubMed ID: 16360543
[TBL] [Abstract][Full Text] [Related]
17. Combination versus sequential single-agent therapy in metastatic breast cancer.
Miles D; von Minckwitz G; Seidman AD
Oncologist; 2002; 7 Suppl 6():13-9. PubMed ID: 12454315
[TBL] [Abstract][Full Text] [Related]
18. Phase I, dose-finding study of capecitabine in combination with docetaxel and epirubicin as first-line chemotherapy for advanced breast cancer.
Venturini M; Del Mastro L; Garrone O; Angiolini C; Merlano M; Bergaglio M; Tolino G; Lambiase A; Baldini A; Canavese G; Rosso R
Ann Oncol; 2002 Apr; 13(4):546-52. PubMed ID: 12056704
[TBL] [Abstract][Full Text] [Related]
19. Future treatment options with capecitabine in solid tumours.
Wilke H
Eur J Cancer; 2002 Feb; 38 Suppl 2():21-5. PubMed ID: 11841932
[TBL] [Abstract][Full Text] [Related]
20. Dose-adjusting capecitabine minimizes adverse effects while maintaining efficacy: a retrospective review of capecitabine for metastatic breast cancer.
Leonard R; Hennessy BT; Blum JL; O'Shaughnessy J
Clin Breast Cancer; 2011 Dec; 11(6):349-56. PubMed ID: 21856245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]